冯·希佩尔-林道病神经系统影响综述
本文综述冯·希佩尔-林道(VHL)病相关中枢神经系统肿瘤的生物学、自然史与处理策略:血管母细胞瘤多位于幕下且呈跳跃式生长,仅对有症状者切除;内淋巴囊肿瘤经三种机制致听前庭症状,现推荐初次发现即切除。
要点
- VHL病相关中枢神经系统病变是发病和死亡的最常见来源。
- 中枢神经系统血管母细胞瘤几乎全部(99%)位于小脑、脑干和脊髓。
- 内淋巴囊肿瘤一经发现即推荐切除。
核心结论
- VHL病相关中枢神经系统肿瘤的新认识重新界定了处理与治疗指征,并可能提供新的靶向治疗策略。
- 血管母细胞瘤仅对有症状者行切除,而新发现的内淋巴囊肿瘤现推荐早期切除。
研究设计与样本
- 综述,回顾VHL病相关中枢神经系统肿瘤的生物学特征、自然史、临床表现与处理策略。
主要发现
- 颅脊血管母细胞瘤几乎全部(99%)位于小脑、脑干和脊髓。
- 肿瘤起源于多能血管母细胞,瘤周囊肿常为血管母细胞瘤相关临床表现的基础(>90%的有症状肿瘤)。
- 前瞻性自然史研究显示中枢神经系统血管母细胞瘤通常呈跳跃式生长。
- VHL病相关内淋巴囊肿瘤经迷路囊侵犯、迷路内出血和内淋巴积水三种机制导致听前庭症状(听力下降、耳鸣和眩晕)。
- 内淋巴囊肿瘤所致听前庭症状与肿瘤大小或进展无关。
关键数值与推荐
- VHL病由位于3号染色体短臂的VHL基因种系突变所致,该基因编码VHL蛋白。
- 因生长方式不可预测,手术切除仅用于有症状病变,因许多肿瘤不出现症状。
- 已定义专用磁共振成像技术以阐明上述每种机制,即使在影像上未识别到肿瘤团块时。
- 内淋巴囊肿瘤现推荐在初次发现肿瘤团块或肿瘤相关症状机制时即行切除。
临床怎么用
- 有症状的中枢神经系统血管母细胞瘤行手术切除。
- 新发现的内淋巴囊肿瘤推荐早期切除。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: von Hippel-Lindau (VHL) disease-associated central nervous system (CNS) lesions include hemangioblastomas and endolymphatic sac tumors (ELSTs), which are associated with significant neurological morbidity and mortality. Recent studies provide critical new biological, diagnostic, and management insights into these tumors. OBSERVATIONS: Biological features, natural history, clinical findings, and management strategies of VHL disease-associated CNS tumors are reviewed. The VHL disease results from a germline mutation of the VHL gene (located on the short arm of chromosome 3), a tumor suppressor that encodes for the VHL protein. Whereas VHL disease is associated with visceral manifestations, CNS lesions are the most common source of morbidity and mortality. Craniospinal hemangioblastomas are almost entirely (99%) found in the cerebellum, brainstem, and spinal cord. These tumors arise from multipotent hemangioblasts. Peritumoral cysts frequently underlie the clinical findings associated with hemangioblastomas (>90% of symptomatic tumors). Prospective natural history studies demonstrate that CNS hemangioblastomas typically grow in a saltatory pattern. Due to this unpredictable growth pattern, surgical resection is reserved for symptomatic lesions, as many tumors do not become symptomatic. Recent studies indicate that VHL disease-associated ELSTs cause audiovestibular morbidity (hearing loss, tinnitus, and vertigo) via 3 mechanisms-otic capsule invasion, intralabyrinthine hemorrhage, and endolymphatic hydrops. Specialized magnetic resonance imaging techniques have been defined to elucidate each of these mechanisms, even when a tumor mass is not identified on imaging. Endolymphatic sac tumors cause audiovestibular morbidity unrelated to size or progression, and resection is now recommended at initial discovery of a tumor mass or a tumor-associated mechanism of morbidity. CONCLUSIONS AND RELEVANCE: New insights into the development, pathobiological origin, natural history, and long-term outcomes of VHL disease-associated CNS tumors have redefined their management and treatment indications and potentially provide new targeted therapeutic strategies. Resection is reserved for symptomatic hemangioblastomas, but early resection of newly detected ELSTs is now recommended.
引用
- Dornbos D, Kim HJ, Butman JA, et al. Review of the Neurological Implications of von Hippel-Lindau Disease. JAMA Neurol. 2018. PMID: 29379961. doi:10.1001/jamaneurol.2017.4469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。